Biostax Corp.
BTAX · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.06 | 0.00 | 0.00 |
| FCF Yield | -6.98% | -4.97% | 0.00% | -2.87% |
| EV / EBITDA | -3.25 | -6.54 | 1.06 | 4.60 |
| Quality | ||||
| ROIC | 43.69% | 64.03% | 15.13% | 10.05% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.17 | 0.16 | -0.12 | – |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | 62.28% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -0.51 | -0.16 | 0.68 | 1.37 |
| Interest Coverage | -8.83 | -9.66 | -3.50 | -1.36 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |